Live Analyst Rating Changes 25671 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Matthew Gillmor CFA
KEY

Matthew Gillmor CFA

KeyBanc
Wall Street Analyst
★★★★★
#289
on 13Foresight · ranked by our own returns
61%
Success Rate
+11.4%
Average Return
20 of 33 calls profitable · +81.2% vs benchmark
S&P 500 (SPY)
🔒 5-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 61% of Matthew Gillmor CFA's ratings turned a profit when each position was held for 1 year — averaging +11.4% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

45 Buy 23 Hold 0 Sell
Matthew's Stock Coverage 17 ratings · 2026-08-19
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
SGRY
Surgery Partners
 Aug 11, 2026 HOLD Strong Buy
+57.3% avg upside
18 analysts
 — -1.9% ·
EVH
Evolent Health
 Aug 10, 2026 HOLD Strong Buy
+112.4% avg upside
19 analysts
 — +15.8% ·
ASTH
Astrana Health
 Aug 07, 2026 HOLD Strong Buy
+47.9% avg upside
16 analysts
 — +14.1% ·
BTSG
BrightSpring Health Services, Inc.
 Aug 03, 2026 BUY Strong Buy
+11.0% avg upside
20 analysts
$80.00
34.53% Upside
 +0.9% ·
ALHC
Alignment Healthcare
 Jul 31, 2026 BUY Strong Buy
+61.8% avg upside
19 analysts
$28.00
111.57% Upside
 -11.1% ·
ACHC
Acadia Healthcare
 Jul 30, 2026 BUY Strong Buy
+48.8% avg upside
17 analysts
$40.00
45.59% Upside
 +9.6% ·
HUM
Humana
 Jul 30, 2026 HOLD Buy
+10.0% avg upside
34 analysts
 — +6.1% ·
HCA
HCA Healthcare
 Jul 27, 2026 BUY Buy
-1.1% avg upside
36 analysts
$435.00
5.68% Upside
 +6.6% ·
INNV
InnovAge Holding
 Jul 20, 2026 HOLD Sell
-34.1% avg upside
12 analysts
 — -4.2% ·
UNH
UnitedHealth
 Jul 14, 2026 BUY Strong Buy
+15.5% avg upside
36 analysts
$475.00
20.49% Upside
 -7.0% ·
EHC
Encompass Health
 Jun 12, 2026 BUY Strong Buy
-8.0% avg upside
22 analysts
 — +20.6% ·
ARDT
Ardent Health Partners, Inc.
 Jun 03, 2026 HOLD Buy
+27.1% avg upside
16 analysts
 — +39.1% ·
ADUS
Addus Homecare
 May 07, 2026 BUY Strong Buy
+8.9% avg upside
19 analysts
 — +19.3% ·
THC
Tenet Healthcare
 May 01, 2026 BUY Strong Buy
-12.2% avg upside
27 analysts
$225.00
16.80% Downside
 +47.4% ·
RDNT
Radnet
 Apr 29, 2026 BUY Strong Buy
+10.0% avg upside
11 analysts
$92.00
24.54% Upside
 +36.6% ·
PRVA
Privia Health Group
 Feb 27, 2026 BUY Strong Buy
+48.0% avg upside
26 analysts
 — -7.4% ·
UHS
Universal Health
 Oct 28, 2025 HOLD Buy
+13.2% avg upside
22 analysts
 — -22.2% ·
🔒 12 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Matthew Gillmor CFA — Frequently Asked Questions
How accurate are Matthew Gillmor CFA's stock ratings?
Based on the calls 13Foresight could measure, about 61% of Matthew's ratings were profitable over a one-year hold, with an average return of +11.4% per rating, or +81.2% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Matthew ranked on 13Foresight?
Matthew Gillmor CFA is currently ranked #289 with a 5-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Matthew cover?
Matthew most recently has ratings on SGRY, EVH, ASTH, BTSG, ALHC, ACHC, HUM, HCA, INNV, UNH, EHC, ARDT and 5 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.